Research graph
References from Perimenopause as a potential window of cardiometabolic remodeling in heart failure with preserved ejection fraction: a missed opportunity for prevention. Local targets link to admitted publications; unresolved targets remain external evidence.
Heart failure with preserved ejection fraction
10.1038/s41572-024-00540-y · 2024 · External reference
Heart failure with preserved ejection fraction: similarities and differences between women and men
10.1016/j.ijcard.2020.01.003 · 2020 · External reference
Sex differences in heart failure
10.1093/eurheartj/ehz835 · 2019 · External reference
Sex-Based differences in heart failure across the ejection fraction Spectrum: phenotyping, and prognostic and therapeutic implications
10.1016/j.jchf.2019.03.011 · 2019 · External reference
Health-Related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial
10.1016/j.jchf.2019.05.015 · 2019 · External reference
Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF trials
10.1016/j.jacc.2024.06.001 · 2024 · External reference
Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction
10.1161/circulationaha.118.034271 · 2018 · External reference
Sex differences in heart failure with preserved ejection fraction: from traditional risk factors to sex-specific risk factors
10.1177/17455057221140209 · 2022 · External reference
Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary
10.1161/circulationaha.119.041886 · 2020 · External reference
The menopausal transition period and cardiovascular risk
10.1038/s41569-023-00926-7 · 2024 · External reference
Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists
10.1093/eurheartj/ehaa1044 · 2021 · External reference
Menopause-Related estrogen decrease and the pathogenesis of HFpEF: JACC review topic of the week
10.1016/j.jacc.2019.12.049 · 2020 · External reference
Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association
10.1161/cir.0000000000000912 · 2020 · External reference
Cardiovascular risk associated with menopause and menopause hormone therapy: a review and contemporary approach to risk assessment
10.1007/s11883-025-01343-6 · 2025 · External reference
Executive summary of the stages of reproductive aging workshop+10: addressing the unfinished agenda of staging reproductive aging
10.1210/jc.2011-3362 · 2012 · External reference
Perimenopause decreases SERCA2a activity in the hearts of a mouse model of ovarian failure
10.3390/biom14060675 · 2024 · External reference
European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause
10.1093/ejendo/lvaf206 · 2025 · External reference
Chronicling menstrual cycle patterns across the reproductive lifespan with real-world data
10.1038/s41598-024-60373-3 · 2024 · External reference
Changes in body composition and weight during the menopause transition
10.1172/jci.insight.124865 · 2019 · External reference
Obesity and menopause
10.1080/09513590.2024.2312885 · 2024 · External reference
Cardiovascular fat, menopause, and sex hormones in women: the SWAN cardiovascular fat ancillary study
10.1210/jc.2015-2110 · 2015 · External reference
Association of epicardial fat with cardiac structure and function and exercise capacity in heart failure with preserved ejection fraction: a systematic review and meta-analysis
10.1016/j.ijcha.2024.101444 · 2024 · External reference
Impact of epicardial adipose tissue on cardiac function and morphology in patients with diastolic dysfunction
10.1002/ehf2.14744 · 2024 · External reference
Linking abnormal fat distribution with HFpEF and diastolic dysfunction: a systematic review, meta-analysis, and meta-regression of observational studies
10.1186/s12944-024-02266-y · 2024 · External reference
The independent associations of anti-müllerian hormone and estradiol levels over the menopause transition with lipids/lipoproteins: the study of Women's Health across the nation
10.1016/j.jacl.2022.11.008 · 2023 · External reference
Low-density lipoprotein subclasses over the menopausal transition and risk of coronary calcification and carotid atherosclerosis: the SWAN heart and HDL ancillary studies
10.1097/gme.0000000000002245 · 2023 · External reference
Sex and gender: critical variables in Pre-clinical and clinical medical research
10.1016/j.cmet.2016.07.017 · 2016 · External reference
Estrogen contributions to microvascular dysfunction evolving to heart failure with preserved ejection fraction
10.3389/fendo.2019.00442 · 2019 · External reference
The NO-cGMP-PKG axis in HFpEF: from pathological mechanisms to potential therapies
10.14336/ad.2022.0523 · 2023 · External reference
Endothelial function is impaired across the stages of the menopause transition in healthy women
10.1210/jc.2012-2244 · 2012 · External reference
Abdominal visceral adipose tissue over the menopause transition and carotid atherosclerosis: the SWAN heart study
10.1097/gme.0000000000001755 · 2021 · External reference
Arterial stiffness and heart failure with preserved ejection fraction
10.3346/jkms.2024.39.e195 · 2024 · External reference
The association between pulse wave velocity and heart failure: a systematic review and meta-analysis
10.3389/fcvm.2024.1435677 · 2024 · External reference
Arterial stiffness assessment in coronary microvascular dysfunction and heart failure with preserved ejection fraction: an initial report from the WISE-CVD continuation study
10.1016/j.ahjo.2024.100390 · 2024 · External reference
The role of coronary microvascular dysfunction in heart failure with preserved ejection fraction
10.1016/j.jacadv.2025.102345 · 2025 · External reference
The prevalence of coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis
10.1007/s10741-023-10362-x · 2024 · External reference
Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta-analysis
10.1002/ehf2.14626 · 2024 · External reference
Focusing on microvascular function in heart failure with preserved ejection fraction
10.1007/s10741-024-10479-7 · 2025 · External reference
Heart failure with preserved ejection fraction: JACC scientific statement
10.1016/j.jacc.2023.01.049 · 2023 · External reference
Inflammation, metabolism, and aging in heart failure with preserved ejection fraction: mechanisms and treatment perspectives
10.1515/jtim-2026-0043 · 2026 · External reference
Associations between menopause, cardiac remodeling, and diastolic function: the CARDIA study
10.1097/gme.0000000000001815 · 2021 · External reference
Development of a chemical reproductive aging model in female rats
10.21769/bioprotoc.3994 · 2021 · External reference
Cardiac changes during the peri-menopausal period in a VCD-induced murine model of ovarian failure
10.1111/apha.13290 · 2019 · External reference
Using 4-vinylcyclohexene diepoxide as a model of menopause for cardiovascular disease
10.1152/ajpheart.00555.2019 · 2020 · External reference
Ovarian failure induced by 4-vinylcyclohexene diepoxide worsens the autonomic cardiovascular response to chronic unpredictable stress in rats
10.1016/j.lfs.2019.04.007 · 2019 · External reference
Female mice with menopause exhibit coronary microvascular disease
10.1152/physiol.2024.39.s1.1712 · 2024 · External reference
The relationship between advanced inflammatory markers and telomere length in cardiac remodeling induced by VCD-induced ovarian failure in female rats
10.36346/sarjmb.2026.v07i02.002 · 2026 · External reference
Pathophysiology of heart failure with preserved ejection fraction
10.1016/j.hfc.2021.02.001 · 2021 · External reference
Conditions and possible mechanisms of VCD-induced ovarian failure
10.1177/026119291504300606 · 2015 · External reference
Hormonal fluctuations in rodent models using 4-vinylcyclohexene diepoxide: a systematic review and meta-analysis
10.1016/j.yhbeh.2025.105680 · 2025 · External reference
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment
10.1007/s00392-024-02396-4 · 2024 · External reference
The future of heart failure with preserved ejection fraction: deep phenotyping for targeted therapeutics
10.1007/s00059-022-05124-8 · 2022 · External reference
The 2022 hormone therapy position statement of the north American menopause society
10.1097/gme.0000000000002028 · 2022 · External reference
Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure
10.1186/s40842-026-00319-y · 2026 · External reference
